AcelRx reports positive trial results for drug-device combo

05/22/2013 | Reuters

AcelRx Pharmaceuticals is on schedule to file for FDA marketing approval in the third quarter after its Sufentanil NanoTab PCA System reached its key goal in a late-stage study. The 426-participant trial showed that compared with a placebo, the drug-device combination reduced pain intensity for patients 48 hours after undergoing hip or knee replacement surgery.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC